GSK and ViiV Showcase Infectious Disease Innovations
GSK and ViiV Healthcare present new infectious disease data at IDWeek 2024, focusing on prevention.
.webp&w=1920&q=75&dpl=dpl_9xUZQSvr7qh8u3ierG8JmijXnhDf)
GSK and ViiV Healthcare are set to unveil new data at IDWeek 2024 in Los Angeles, focusing on their infectious disease pipeline, which includes 60 abstracts spanning vaccines and treatments for respiratory syncytial virus (RSV), herpes zoster, urinary tract infections, and HIV. Key highlights will include data on their RSV vaccine, Arexvy, and gepotidacin, an investigational antibiotic targeting uUTIs.
The presentations aim to address significant public health challenges, including the rising threat of antimicrobial resistance (AMR). GSK emphasizes its commitment to innovative solutions in prevention and treatment, aiming to enhance global health outcomes.
GSK has a long-standing history of pioneering efforts in infectious diseases, leveraging its diverse portfolio to develop preventative and therapeutic treatments. Their ongoing research and strategic collaborations underscore their dedication to tackling health issues with high unmet needs.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
More from Pharma News
All stories →
Bristol-Myers Squibb Gains FDA Accelerated Approval for Iberdomide in Relapsed or Refractory Multiple Myeloma
Eton Pharmaceuticals Gains FDA Fast Track for AMGLIDIA and Targets 2027 NDA with ASN-001 Acquisition
Discussion